Back to Search
Start Over
Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity.
- Source :
-
Scientific reports [Sci Rep] 2020 Jul 02; Vol. 10 (1), pp. 10923. Date of Electronic Publication: 2020 Jul 02. - Publication Year :
- 2020
-
Abstract
- Neurofilament light chain (NfL) has been demonstrated to correlate with multiple sclerosis disease severity as well as treatment response. Nevertheless, additional serum biomarkers are still needed to better differentiate disease activity from disease progression. The aim of our study was to assess serum glial fibrillary acid protein (s-GFAP) and neurofilament light chain (s-NfL) in a cohort of 129 multiple sclerosis (MS) patients. Eighteen primary progressive multiple sclerosis (PPMS) and 111 relapsing remitting MS (RRMS) were included. We showed that these 2 biomarkers were significantly correlated with each other (R = 0.72, p < 0.001). Moreover, both biomarkers were higher in PPMS than in RRMS even if multivariate analysis only confirmed this difference for s-GFAP (130.3 ± 72.8 pg/ml vs 83.4 ± 41.1 pg/ml, p = 0.008). Finally, s-GFAP was correlated with white matter lesion load and inversely correlated with WM and GM volume. Our results seem to confirm the added value of s-GFAP in the context of multiple sclerosis.
- Subjects :
- Adult
Cross-Sectional Studies
Female
Humans
Male
Middle Aged
Multiple Sclerosis, Chronic Progressive pathology
Multiple Sclerosis, Relapsing-Remitting pathology
Neurofilament Proteins blood
Severity of Illness Index
Brain pathology
Glial Fibrillary Acidic Protein blood
Magnetic Resonance Imaging
Multiple Sclerosis, Chronic Progressive blood
Multiple Sclerosis, Relapsing-Remitting blood
White Matter pathology
Subjects
Details
- Language :
- English
- ISSN :
- 2045-2322
- Volume :
- 10
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Scientific reports
- Publication Type :
- Academic Journal
- Accession number :
- 32616916
- Full Text :
- https://doi.org/10.1038/s41598-020-67934-2